《两步点滴法美平在儿科中的应用》由会员分享，可在线阅读，更多相关《两步点滴法美平在儿科中的应用（71页珍藏版）》请在金锄头文库上搜索。
1、美平在儿科的临床应用住友制药市场部l儿科感染特点及致病菌分布情况l美平抗菌谱广，抗菌活性强l美平具有优异的疗效l运用PK/PD理论，优化抗生素使用l美平推荐剂量内容儿科感染的特点在儿科抗感染治疗中，除了需要考虑一些和成人患者相同的因在儿科抗感染治疗中，除了需要考虑一些和成人患者相同的因素，还面对更多的挑战：小儿处在生长发育过程中，许多器官、组素，还面对更多的挑战：小儿处在生长发育过程中，许多器官、组 织还不成熟，相对功能低下或比较脆弱，更易出现异常的生理和病织还不成熟，相对功能低下或比较脆弱，更易出现异常的生理和病 理改变。儿童感染中多重感染较成年人更多见，容易发展成为重度理改变。儿童感染中多
2、重感染较成年人更多见，容易发展成为重度 感染。感染。因此要充分考虑药物的毒性和不良反应，尽量避免对儿童生长因此要充分考虑药物的毒性和不良反应，尽量避免对儿童生长发育带来的不良影响。发育带来的不良影响。对于儿科感染，经验性选择广谱抗生素单药治疗可更少发 生抗生素相关的毒性反应、药物相互作用、配药及护理时 间、外周静脉注射等，比联合用药更具有优势。 新生儿细菌感染时抗生素的选择策略l抗菌药物使用的时机l对病情较严重或弱小的婴儿，一旦有脓毒 血症可疑迹象，应作必要的有效治疗l使用抗生素前收集各种标本，应及时使用 抗菌药物我国儿童死亡的流行病学调查 感染性疾病的死亡率占到儿童死亡的一半以上，肺炎 是第
3、一位死因 Bryce, J., Boschi-Pinto, C. 137:1283-1288不恰当治疗经常归咎于抗生素的耐药l l存在抗生素耐药时更易出现不恰当的治疗存在抗生素耐药时更易出现不恰当的治疗l l细菌对抗生素的耐药也常常与不恰当的治疗相关细菌对抗生素的耐药也常常与不恰当的治疗相关Adapted from Kollef MH. Clin Infect Dis. 2000;31(suppl 4):S131S138.不恰当治疗 (%)010203040不动杆菌属铜绿假单胞菌金葡菌其他肺炎克雷伯耐药和非耐药感染：病死率的对比Roberts RR et al. Clin Infect Dis
4、 2009; 49:1175-84Roberts RR et al. Clin Infect Dis 2009; 49:1175-84l耐药菌感染死亡率更高。l lGarnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz
5、-Leyba C. Impact of adequate antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med Impact of adequate antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003; 31:2742-2751.2003; 31:2742-2
6、751.l lKollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest
7、1999; 115:462-474.among critically ill patients. Chest 1999; 115:462-474.l lRello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ve
8、ntilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196-200.pneumonia. Am J Respir Crit Care Med 1997; 156:196-200.l lIregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic Iregui M, Ward S, Sherman G, Fraser VJ, Ko
9、llef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002;122:262-268. treatment for ventilator-associated pneumonia. Chest 2002;122:262-268. l lLuna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC
10、. Impact of BAL data on the therapy and outcome of Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-685. ventilator-associated pneumonia. Chest 1997; 111:676-685. l lLeibovi
11、ci L, Drucker M, Konigsberger H et al. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Leibovici L, Drucker M, Konigsberger H et al. Septic shock in bacteremic patients: risk factors, features and prognosis. Scand J Infect Dis 1997; 29:71-75. Infect Dis 1997; 29:71
12、-75. l lValles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: Valles J, Rello J, Ochagavia A, Garnacho J, Alcala MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriat
13、e antibiotic therapy on survival. Chest 2003; 123:1615-1624. impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-1624. l lIbrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream Ibrahim EH, Sherman G,
14、Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155. infections on patient outcomes in the ICU setting. Chest 2000; 118:146-155. l lAlvarez-Lerma F. Modification of empiric antibio
15、tic treatment in patients with pneumonia acquired in the intensive care unit. ICUAlvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU -Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-394. MacArthur RD, Mille
16、r M, Albertson T et al. Adequacy -Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-394. MacArthur RD, Miller M, Albertson T et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS Trial. Clin Infect Dis 2003; of early empiric antibiotic treatment and survival in severe sepsis: Experience from the MONARCS Trial. Clin Infect Dis 2003; 38:284-288.38:284-288.l lHarbarth S, Garbino J, Pugin J et al. Inappropr
